| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
| ln Vivo |
Dobutamine hydrochloride acts quickly and has a brief half-life [2]. ?In wild-type mice, intraperitoneal injections of dobutamine hydrochloride (0.15–20 mg/kg) result in dose-dependent increases in left ventricular function and heart rate [3]. ?In wild-type mice, high doses of dobutamine hydrochloride cause notable inotropic, relaxing, and chronotropic cardiac responses [3]. ?In Tgαq*44 mice, low-dose dobutamine hydrochloride markedly improved inotropic and relaxing cardiac performance without causing any alterations to the chronotropic system [3]. ?Only at high doses does dobutamine hydrochloride raise heart rate, but it also causes a loss of diastolic and inotropic cardiac functional reserve [3]. ?Dobutamine hydrochloride stimulates β-2 receptors to improve alveolar fluid evacuation in ventilated rats [4].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Tgαq*44 mouse (heart failure model) [3]
Doses: low dose 0.15mg/kg, 0.5mg/kg, high dose 1.5mg/kg, 5mg/kg, 20mg/kg: intraperitoneal (ip) injection Experimental Results:Low Low and high doses produced differential responses in cardiac function in mice with heart failure. |
| References |
[1]. Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975 Jan;36(1):185-96.
[2]. Vallet B, et al. Dobutamine: mechanisms of action and use in acute cardiovascular pathology. Ann Cardiol Angeiol (Paris). 1991 Jun;40(6):397-402. [3]. Tyrankiewicz U , et al. Characterization of the cardiac response to a low and high dose of dobutamine in the mouse model of dilated cardiomyopathy by MRI in vivo. J Magn Reson Imaging. 2013 Mar;37(3):669-77. [4]. Tibayan FA, et al. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):438-44. |
| Molecular Formula |
C18H24CLNO3
|
|---|---|
| Molecular Weight |
337.8411
|
| CAS # |
49745-95-1
|
| Related CAS # |
Dobutamine;34368-04-2;Dobutamine tartrate;101626-66-8;(rac)-Dobutamine-d4 hydrochloride;1246815-74-6;(rac)-Dobutamine-d6 hydrochloride;1246818-96-1
|
| SMILES |
Cl[H].O([H])C1=C(C([H])=C([H])C(=C1[H])C([H])([H])C([H])([H])N([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])O[H]
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 33 mg/mL (~97.68 mM)
H2O : ~20 mg/mL (~59.20 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 16.67 mg/mL (49.34 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9600 mL | 14.7999 mL | 29.5998 mL | |
| 5 mM | 0.5920 mL | 2.9600 mL | 5.9200 mL | |
| 10 mM | 0.2960 mL | 1.4800 mL | 2.9600 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA